- Short report
- Open Access
Impaired fasting glucose as an independent risk factor for hypertension among healthy middle-aged Japanese subjects with optimal blood pressure: the Yuport Medical Checkup Centre retrospective cohort study
© Morio et al.; licensee BioMed Central Ltd. 2013
- Received: 11 June 2013
- Accepted: 16 December 2013
- Published: 20 December 2013
This study aimed at investigating whether impaired fasting glucose (IFG) is an independent risk factor for incident hypertension among middle-aged Japanese subjects with optimal blood pressure (OBP).
This retrospective cohort study was conducted in 2943 non-diabetic and non-hypertensive subjects aged 40–64 years, who participated in a voluntary health check-up program during the baseline (1998–2002) and follow-up periods (2002–2006). A multiple logistic regression model was utilized to calculate the odds ratio (OR) of incident hypertension among men and women with IFG and OBP. OBP was defined as systolic blood pressure (SBP) <120 mmHg and diastolic blood pressure (DBP) <80 mmHg, with no known history of hypertension. In this study, hypertension was defined as SBP ≥140 mmHg and DBP ≥90 mmHg or by a self-reported clinical diagnosis of hypertension. After the mean follow-up period of 5.6 years, the incidence of hypertension in men and women was 5.7% (73/1270) and 3.8% (62/1673), respectively. The age-adjusted ORs for incident hypertension in men and women with IFG were 1.95 (95% CI, 1.21–3.15) and 3.54 (95% CI, 2.00–6.27), respectively. After adjusting for age, systolic blood pressure, body mass index, total cholesterol, triglyceride, high-density lipoprotein cholesterol, and uric acid, the ORs for hypertension were 1.66 (95% CI; 1.02–2.70) for men and 2.62 (95% CI, 1.45–4.73) for women.
The study results show that IFG may act as an independent risk factor for developing hypertension in individuals with OBP.
- Fasting plasma glucose
- Impaired fasting glucose
- Optimal blood pressure
Hypertension and diabetes are the leading morbidities affecting the general population, often concurrently, as there is substantial overlap between hypertension and diabetes in both etiology and disease mechanism [1–3]. The association between elevated blood pressure and dysglycemia has also recently been of interest .
In 1997, the American Diabetes Association (ADA) introduced the term ‘impaired fasting glucose’ (IFG), defined as a fasting plasma glucose (FPG) level of 110–125 mg/dL (IFG1997), to describe a prediabetic state of dysglycemia . Accordingly, researchers began to examine whether IFG may be an independent risk factor for the development of hypertension as well. However, previous findings were inconsistent [6–10]. Although IFG and elevated FPG emerged as independent risk factors for the development of hypertension in 3 prospective studies [6–8], this relationship was not found in 2 other studies after adjusting for body mass index (BMI) or waist circumference [9, 10].
Central obesity is a well-known risk factor for both diabetes and hypertension [3, 11], and is thought to be a common pathway whereby obesity affects both diseases [1, 2]. Simone et al. reported that abdominal obesity was a major predictor of the development of hypertension even at optimal blood pressure (OBP) , which suggests that atherogenic risk factors could play a major role in atherosclerosis even when blood pressure is low or at optimal levels.
The association of IFG and hypertension in those with OBP has not been investigated thoroughly. Furthermore, although the ADA lowered the FPG concentration range for diagnosis of IFG from 110–125 mg/dL to 100–125 mg/dL in 2003 , there have been no studies conducted to determine whether this new criterion for IFG is predictive of the development of hypertension.
In this study, we investigated whether the new criterion for IFG could be considered as an independent risk factor for incident hypertension among healthy middle-aged Japanese subjects with OBP.
We used a health screening program cohort of 13,734 healthy middle-aged Japanese subjects, who received routine medical check-ups during the baseline period between April 1998 and March 2002 at the Yuport Medical Checkup Centre in Tokyo, which has been described previously [12–15]. If subjects received more than 1 check-up during the baseline period, the initial check-up data were used. The 4-year follow-up period ended between April 2002 and March 2006, and the 6,290 subjects who did not have follow-up data were excluded. If subjects received more than 1 check-up during the follow-up period, all data were used to identify incident hypertension. This study excluded 424 subjects who had a baseline FPG ≥126 mg/dL, HbA1c ≥6.5%, or self-reported clinically diagnosed diabetes, as well as 4067 subjects with a baseline SBP ≥120 mmHg, DBP ≥80 mmHg, or self-reported clinical diagnosis of hypertension. The remaining 2943 non-diabetic and non-hypertensive patients were included as study subjects (mean follow-up, 5.6 ± 1.6 years).
Clinical and laboratory procedures
All medical check-ups followed the same procedures during both the baseline and follow-up periods. Resting blood pressure was measured twice by well-trained nurses using a mercury column sphygmomanometer, after each subject sat quietly for at least 5 min. The average of the 2 measurements was used for analysis.
All blood samples were collected after an overnight fast. Blood samples were measured on the same autoanalyzer in the laboratory at the medical center. Plasma glucose levels were measured using the hexokinase-G6PD method (Denka Seiken, Niigata, Japan) with an interassay coefficient of variation (CV) ≤3.0%. Hemoglobin A1c (HbA1c) levels were measured using a latex immunoagglutination assay method (Determiner HbA1c, Kyowa Medex, Tokyo, Japan) with an interassay CV of 1.7–2.1%, which was aligned with the units used by the Japan Diabetes Society (JDS). The JDS value for HbA1c was converted into National Glycohemoglobin Standardization Program (NGSP) units in this study, which was calculated by the formula: HbA1c (NGSP) = HbA1c (JDS) + 0.4 . Other blood tests, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), creatinine (Cr), and uric acid (UA), were measured using enzymatic methods (reagents supplied by Daiichi Pure Chemicals, Tokyo, Japan). Low-density lipoprotein cholesterol (LDL-C) was calculated by the Friedewald equation .
In accordance with the Private Information Protection Law, information that might identify subjects was kept confidential. This study was approved by the review board of the Yuport Medical Checkup Centre, and informed consent for anonymous participation in this study was obtained from each subject at every check-up.
Diagnosis of hypertension and IFG
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) criteria were utilized  to define OBP as SBP <120 mmHg and DBP <80 mmHg. Hypertension was defined as SBP ≥140 mmHg and DBP ≥90 mmHg, or as self-reported clinically diagnosed hypertension. FPG categories were defined by using the 2003 ADA criteria  as normal fasting glucose (NFG); FPG ≤99 mg/dL and IFG; FPG of 100–125 mg/dL.
Baseline characteristics for all subjects are presented as mean ± standard deviation (SD). A Students t-test or chi-square test was used to test for differences in mean values and frequencies between men and women. We calculated the odds ratios (ORs) and 95% confidence intervals (CIs) to assess the association between IFG (versus NFG) at baseline and the incidence of hypertension at follow-up using multiple logistic regression analyses. We used two multivariable models: model 1, adjusted for age; and model 2, adjusted for age, BMI, SBP, TC, TG, HDL-C and UA. All reported P-values were two-tailed, and P < 0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 19 (SPSS Inc., Japan).
Baseline characteristics and incidence of hypertension
N = 2943
N = 1270 (43.2%)
N = 1673 (56.8%)
51.7 ± 6.7
51.0 ± 6.7
52.2 ± 6.7
22.1 ± 2.6
22.7 ± 2.6
21.5 ± 2.6
107.5 ± 7.9
108.8 ± 7.2
106.5 ± 8.3
65.8 ± 6.2
67.5 ± 5.6
64.5 ± 6.4
92.8 ± 8.5
96.1 ± 8.5
90.4 ± 7.5
5.4 ± 0.4
5.4 ± 0.4
5.4 ± 0.4
201.6 ± 33.7
194.8 ± 32.5
206.7 ± 33.7
102.6 ± 62.0
124.8 ± 76.3
85.7 ± 40.9
60.3 ± 15.6
52.7 ± 13.3
66.0 ± 14.7
120.8 ± 30.1
117.1 ± 30.2
123.6 ± 30.8
0.70 ± 0.15
0.82 ± 0.13
0.61 ± 0.09
5.0 ± 1.3
5.9 ± 1.2
4.4 ± 0.9
5.6 ± 1.6
5.7 ± 1.5
5.5 ± 1.6
Odds ratio for incident hypertension in middle-aged Japanese subjects with OBP by sex
FPG categories at baseline
Incidence of hypertension, (%)
Incidence of hypertension, (%)
OR (95% CI)
OR (95% CI)
IFG vs. NFG
IFG vs. NFG
TC (per 10 mg/dL)
TG (per 10 mg/dL)
HDL-C (per 10 mg/dL)
The main finding of this study was that IFG may act as an independent risk factor for the development of hypertension in middle-aged healthy Japanese subjects with OBP. In 1997, after the ADA introduced IFG1997, various prospective studies have demonstrated that impaired glucose tolerance (IGT), another form of dysglycemia, was an independent risk factor for incident hypertension [4, 19–21]. However, the results from previous investigations of the association between IFG1997 or elevated FPG and the risk for hypertension are conflicting [6–10], with 3 positive and 2 negative results.
This study has some methodological strengths as compared with previous studies. First, our cohort population was relatively large and had a single homogenous ethnicity. Second, all subjects were examined at one site, and laboratory samples were measured using the same method both at baseline and follow-up.
Our study had several limitations. First, we could not include several possible confounding variables that are known hypertension risk factors, such as plasma insulin, family history, alcohol and salt consumption, smoking, waist circumference, and socioeconomic status. These variables could be relevant for explaining the relationship between IFG and the risk for hypertension. Second, incident hypertension was defined by a single basal measurement of blood pressure, which was repeated at follow-up, or by a self-reported clinical diagnosis of hypertension. Third, the study subjects were men and women who had regular check-ups at a medical center in Tokyo, and they may be a healthier subset of the general population.
In summary, this study demonstrated an association between IFG and the development of hypertension among relatively lean Japanese subjects with OBP after the ADA lowered the FPG threshold value for IFG from 110 to 100 mg/dL in 2003. The findings may help clinicians identify those who are at higher risk for hypertension.
We are grateful to Mrs. Tetsuya Hayashi and Kiyonori Uchiyama for their assistance with data collection.
- Cheung BM, Li C: Diabetes and hypertension: is there a common metabolic pathway?. Curr Atheroscler Rep. 2012, 14 (2): 160-166. 10.1007/s11883-012-0227-2.PubMed CentralView ArticlePubMedGoogle Scholar
- Cheung BM: The hypertension-diabetes continuum. J Cardiovasc Pharmacol. 2010, 55 (4): 333-339. 10.1097/FJC.0b013e3181d26430.View ArticlePubMedGoogle Scholar
- Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003, 289 (1): 76-79.View ArticlePubMedGoogle Scholar
- Cheung BM, Wat NMS, Tso AWK, Tam S, Thomas GN, Leung GM, Tse HF, Woo J, Janus ED, Lau CP, Lam TH, Lam KS: Association between raised blood pressure and dysglycemia in Hong Kong Chinese. Diabetes Care. 2008, 31 (9): 1889-1891. 10.2337/dc08-0405.PubMed CentralView ArticlePubMedGoogle Scholar
- The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997, 20 (7): 1183-1197.View ArticleGoogle Scholar
- Bjørnholt JV, Erikssen G, Kjeldsen SE, Bodegard J, Thaulow E, Erikssen J: Fasting blood glucose is independently associated with resting and exercise blood pressures and development of elevated blood pressure. J Hypertens. 2003, 21 (7): 1383-1389. 10.1097/00004872-200307000-00029.View ArticlePubMedGoogle Scholar
- Fagot-Campagna A, Balkau B, Simon D, Ducimetiere P, Eschwege E: Is insulin an independent risk factor for hypertension? The Paris Prospective Study. Int J Epidemiol. 1997, 26 (3): 542-550. 10.1093/ije/26.3.542.View ArticlePubMedGoogle Scholar
- Suematsu C, Hayashi T, Fujii S, Endo G, Tsumura K, Okada K, Morii H: Impaired fasting glucose and the risk of hypertension in Japanese men between the 1980s and the 1990s. The Osaka Health Survey. Diabetes Care. 1999, 22 (2): 228-232. 10.2337/diacare.22.2.228.View ArticlePubMedGoogle Scholar
- Wang W, Lee ET, Fabsitz RR, Devereux R, Best L, Welty TK, Howard BV: A longitudinal study of hypertension risk factors and their relation to cardiovascular disease: the strong heart study. Hypertension. 2006, 47 (3): 403-409. 10.1161/01.HYP.0000200710.29498.80.View ArticlePubMedGoogle Scholar
- Levin G, Kestenbaum B, Ida Chen YD, Jacobs DR, Psaty BM, Rotter JI, Siscovick DS, de Boer IH: Glucose, insulin, and incident hypertension in the multi-ethnic study of atherosclerosis. Am J Epidemiol. 2010, 172 (10): 1144-1154. 10.1093/aje/kwq266.PubMed CentralView ArticlePubMedGoogle Scholar
- Davy KP, Hall JE: Obesity and hypertension: two epidemics or one?. Am J Physiol Regul Intergr Comp Physiol. 2004, 286 (5): R803-R813. 10.1152/ajpregu.00707.2003.View ArticleGoogle Scholar
- Inoue K, Kashima S, Ohara C, Matsumoto M, Akimoto K: Concordance of two diabetes diagnostic criteria using fasting plasma glucose and hemoglobin A1c: the Yuport Medical Checkup Centre study. PLoS One. 2012, 7 (10): e47747-10.1371/journal.pone.0047747.PubMed CentralView ArticlePubMedGoogle Scholar
- Inoue M, Inoue K, Akimoto K: Effects of age and sex in the diagnosis of type 2 diabetes using glycated haemoglobin in Japan: the Yuport Medical Checkup Centre study. PLoS One. 2012, 7 (7): e40375-10.1371/journal.pone.0040375.PubMed CentralView ArticlePubMedGoogle Scholar
- Inoue K, Matsumoto M, Akimoto K: Fasting plasma glucose and HbA1c as risk factors for type 2 diabetes. Diabet Med. 2008, 25 (10): 1157-1163. 10.1111/j.1464-5491.2008.02572.x.View ArticlePubMedGoogle Scholar
- Inoue K, Matsumoto M, Akimoto K: The threshold for definition of impaired fasting glucose in a Japanese population. Diabet Med. 2009, 26 (11): 1175-1178. 10.1111/j.1464-5491.2009.02850.x.View ArticlePubMedGoogle Scholar
- Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18: 499-502.PubMedGoogle Scholar
- Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ, National High Blood Pressure Education Program Coordinating Committee: The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003, 289 (19): 2560-2572. 10.1001/jama.289.19.2560.View ArticlePubMedGoogle Scholar
- Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003, 26 (11): 3160-3167.View ArticlePubMedGoogle Scholar
- Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, Shitrit A, Fuchs Z: Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest. 1985, 75 (3): 809-817. 10.1172/JCI111776.PubMed CentralView ArticlePubMedGoogle Scholar
- de Simone G, Devereux RB, Chinali M, Roman MJ, Best LG, Welty TK, Lee ET, Howard BV: Risk factors for arterial hypertension in adults with initial optimal blood pressure: the strong heart study. Hypertens. 2006, 47 (2): 162-167. 10.1161/01.HYP.0000199103.40105.b5.View ArticleGoogle Scholar
- Boyko EJ, Barr EL, Zimmet PZ, Shaw JE: Two-hour glucose predicts the development of hypertension over 5 years: the AusDiab study. J Hum Hypertens. 2008, 22 (3): 168-176. 10.1038/sj.jhh.1002316.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.